Company / R&D Expense
AYTU BIOPHARMA, INC R&D Expense History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.3M
FY2025
5-year range
$1.3M / $12.7M
FY2021-FY2025
Trend
-52.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 3 consecutive years, from $13M in FY2022 to $1M in FY2025.
Based on SEC 10-K filings.
$1M in FY2025 with a 10-year CAGR of -8.5%.
Declined from $4M to $1M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -52.9%
- 5-Year CAGR
- -5.1%
- 10-Year CAGR
- -8.5%
Key checks
Key Insights
- AYTU BIOPHARMA, INC's r&d expense has declined for 3 consecutive years.
- 5-year CAGR of -5.1%, indicating a declining trend.
- In FY2025, r&d expense decreased 52.1% year-over-year.
- Peak r&d expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3M | -52.1% |
| FY2024 | $2.8M | -32.4% |
| FY2023 | $4.1M | -67.7% |
| FY2022 | $12.7M | +125.2% |
| FY2021 | $5.6M | +226.5% |
| FY2020 | $1.7M | +927.5% |
| FY2018 | $167.6K | -82.5% |
| FY2017 | $959.9K | -84.3% |
| FY2016 | $6.1M | +90.3% |
| FY2015 | $3.2M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026